Literature DB >> 10590323

Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens.

W Zeng1, D C Jackson, J Murray, K Rose, L E Brown.   

Abstract

A synthetic peptide corresponding to a sequence from influenza hemagglutinin was used as a model antigen to study the immunogenicity of polyoxime constructs. In the absence of any adjuvant, tetrameric forms of different polyoxime constructs did not elicit an antibody response. High and long-lasting levels of antibody were induced, however, by polyoxime constructs to which Pam3Cys (tripalmitoyl-S-glyceryl cysteine) was attached. Comparable serum antibody levels were achieved with Tetraoxime-Pam3Cys administered by the intraperitoneal or intranasal routes to those obtained when the monomeric peptide was administered by the intraperitoneal route in complete Freund's adjuvant (CFA). Mice receiving Tetraoxime-Pam3Cys and Pam3Cys-peptide intranasally developed peptide-specific antibody secreting cells (ASCs) in their lungs and mediastinal lymph nodes. At low dose, the Tetraoxime-Pam3Cys induced higher levels of antibody compared to those elicited by the monomeric Pam3Cys-peptide delivered by either route. These results show that lipo-tetraoxime constructs assembled by polyoxime chemistry can be potent inducers of systemic and mucosal immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590323     DOI: 10.1016/s0264-410x(99)00346-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Authors:  Colleen Olive; Michael R Batzloff; Anikó Horváth; Allan Wong; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 2.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens.

Authors:  Colleen Olive; Michael Batzloff; Aniko Horváth; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus.

Authors:  S Ghosh; J Walker; D C Jackson
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

5.  Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses.

Authors:  Lbachir BenMohamed; Radhika Krishnan; Catherine Auge; James F Primus; Don J Diamond
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

6.  Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone.

Authors:  Ester J Kwon; Jurate Lasiene; Berit E Jacobson; In-Kyu Park; Philip J Horner; Suzie H Pun
Journal:  Biomaterials       Date:  2009-12-09       Impact factor: 12.479

7.  Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles.

Authors:  Yoshio Fujita; Hiroaki Taguchi
Journal:  Chem Cent J       Date:  2011-08-23       Impact factor: 4.215

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.